Results 141 to 150 of about 2,650 (185)

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study. [PDF]

Clin Ophthalmol
Chakraborty S, Sheth JU, Ganguly S, Reddy R.   +3 more
europepmc   +1 more source

Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Bousamri A, Al-Shehri M, Mestarihi M, Almutairi TB, Alaredhi M, Mahanna B, Alharbi F.   +6 more
europepmc   +1 more source

Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study. [PDF]

J Pers Med
Hwang S, Hong RK, Hong EH, Kang MH, Shin YU.   +4 more
europepmc   +1 more source

VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study. [PDF]

Graefes Arch Clin Exp Ophthalmol
Kilani A, Vogt D, Moysidi V, Assaf A, Wolf A, Vounotrypidis E.   +5 more
europepmc   +1 more source

Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland. [PDF]

BMC Health Serv Res
Seweryn M, Kopel J, Augustynska J, Mikołajewicz A, Toro MD, Rejdak R.   +5 more
europepmc   +1 more source

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study. [PDF]

J Clin Med
Teper S, Ledwoń D, Romaniszyn-Kania P, Sendecki A, Tuszy A, Nycz J, Mitas AW, Figurska M, Wylęgała E, Rękas M.   +9 more
europepmc   +1 more source

Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability. [PDF]

Ophthalmol Ther
Avery R, Diack C, Holekamp N, Lhor M, Mar F, Maass K.   +5 more
europepmc   +1 more source

Consensus of Expert Recommendations for the Safe Administration of Brolucizumab in Neovascular Age-related Macular Degeneration. [PDF]

Korean J Ophthalmol
Song JR, Park KH, Kang SW, Chin HS, Yu SY, Park YH, Kim YC, Lee JE, Lim ST, Kim JG, Kim CR, Sagong M, Oh HS, Lee CS, Woo SJ.   +14 more
europepmc   +1 more source

Management of diabetic macular edema: from anti-VEGF to emerging therapies. [PDF]

Front Med (Lausanne)
Ji M, Wei W, Gong H, Zhang G.
europepmc   +1 more source

Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases. [PDF]

BMJ Open Ophthalmol
Xu S, Song Z, Li Y, Bai J, Wang D, Wang E, Wang J.   +6 more
europepmc   +1 more source